SCHEMBL21812467

SCHEMBL21812467

Cc1cc(-c2cc3cc(-c4cc(C)nc(C)c4)ccc3[nH]2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 7/20 0.47
TLR7 Q9NYK1 7/20 0.47
TLR9 Q9NR96 5/20 0.47
CDK5 Q00535 2/20 0.47
CDK5R1 Q15078 2/20 0.47
DYRK1A Q13627 1/20 0.43
CYP1A1 P04798 1/20 0.42
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31317851 0.95 CDK5 (0.50) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812348 0.95 CDK5 (0.50) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL31317802 0.90 CDK5 (0.49) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812320 0.90 CDK5 (0.49) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812394 0.87 WNT3A (0.47) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL31317870 0.87 WNT3A (0.47) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL31317812 0.87 TLR8 (0.55) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812425 0.87 CDK5 (0.53) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812423 0.87 TLR8 (0.55) TLR8TLR7TLR9CDK5CDK5R1
SCHEMBL21812369 0.86 CDK5 (0.43) TLR8TLR7TLR9CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628669-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2020-04-01 EP claimed
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP disclosed
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2022-02-03 US disclosed
EP-3628669-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2020-04-01 EP disclosed
EP-3628669-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2020-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CYBB, NOX1, NOX4 TLR8 4076/4885TLR7 4348/4885TLR9 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.